Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By Alton Parrish (Reporter)
Contributor profile | More stories
Story Views
Now:
Last Hour:
Last 24 Hours:
Total:

Scientists Discover Key Element of Strong Antibody Response to COVID-19

% of readers think this story is Fact. Add your two cents.


A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19. The findings support many vaccine strategies being used to tackle the new coronavirus.

The scientists, whose study appears July 13 in Science, reviewed data on nearly 300 anti-SARS-CoV-2 antibodies that their labs and others have found in convalescent COVID-19 patients over the past few months. They noted that a subset of these antibodies is particularly powerful at neutralizing the virus–and these potent antibodies are all encoded, in part, by the same antibody gene, IGHV3-53.

The scientists used a powerful tool known as X-ray crystallography to image two of these antibodies attached to their target site on SARS-CoV-2. The resulting atomic-structure details of this interaction should be useful to vaccine designers, as well as to scientists hoping to develop antiviral drugs targeting the same site on SARS-CoV-2.

Transmission electron microscopic image of an isolate from the first U.S. case of COVID-19, formerly known as 2019-nCoV. The spherical viral particles, colorized blue, contain cross-section through the viral genome, seen as black dots.
Coronavirus

Credit: CDC

Prior research suggests that antibodies encoded by IGHV3-53 are generally present, at least in small numbers, in healthy people’s blood. The results therefore offer hope that using a vaccine to boost levels of these ever-present antibodies will protect adequately against the virus.

“This type of antibody has been isolated frequently in studies of COVID-19 patients, and we can now understand the structural basis for its interaction with SARS-CoV-2,” says the study’s senior author Ian Wilson, DPhil, Hansen Professor of Structural Biology and Chair of the Department of Integrative Structural and Computational Biology at Scripps Research.

“This study provides important inspiration for effective COVID-19 vaccine design,” says co-author Dennis Burton, PhD, professor and co-chair of the Department of Immunology and Microbiology at Scripps Research.

The research was a collaboration chiefly involving the Wilson and Burton labs, and the Scripps Research-based Neutralizing Antibody Center of IAVI, a prominent non-profit vaccine research organization.

SARS-CoV-2 so far has infected more than 12 million people around the world and killed more than 500,000, in addition to causing widespread socioeconomic disruption and damage. Developing an effective vaccine to stop the pandemic is currently the world’s top public health priority.

Although several potential vaccines are already in clinical trials, scientists don’t yet have a full understanding of the molecular features that would define a protective antibody response. In the new study, the scientists took a big step toward that goal.

The team started by analyzing 294 different SARS-CoV-2-neutralizing antibodies isolated from COVID-19 patients’ blood over the past few months. Antibodies are Y-shaped proteins made in immune cells called B-cells. Each B-cell makes a specific antibody type, or clone, which is encoded by a unique combination of antibody genes in the cell. The scientists found that an antibody gene called IGHV3-53 was the most common of the genes for the 294 antibodies, encoding about 10 percent of them.

The scientists also noted that the IGHV3-53-encoded antibodies in their study contain an unusually short variant of the CDR H3 loop, normally a key target-binding element. These antibodies are nevertheless very potent against SARS-CoV-2 when compared to other antibodies not encoded by IGHV3-53.

A powerful response right off the bat

The IGHV3-53 antibodies had yet another property suggesting that boosting their numbers would be a good and achievable aim for a SARS-CoV-2 vaccine: They appeared to have mutated only minimally from the original versions that would be circulating, initially in small numbers, in the blood of healthy people.

Normally, when activated by an encounter with a virus to which they fit, B-cells will start proliferating and also mutating parts of their antibody genes, in order to generate new B-cells whose antibodies fit the viral target even better. The more mutations needed for this “affinity maturation” process to generate virus-neutralizing antibodies, the harder it can be to induce this same process with a vaccine.

Fortunately, the IGHV3-53 antibodies found in the study seemed to have undergone little or no affinity maturation and yet were already very potent at neutralizing the virus–which hints that a vaccine may be able to induce a protective response from these potent neutralizers relatively easily.

“Coronaviruses have been around for hundreds to thousands of years, and one can imagine that our immune system has evolved in such a way that we carry antibodies like these that can make a powerful response right off the bat, so to speak” Wilson says.

Map for vaccine-makers, gauge for clinical trials

Wilson’s team used high-resolution X-ray crystallography to image two different IGHV3-53 antibodies bound to their target on SARS-CoV-2. This target, known as the receptor binding site, is a crucial structure on the viral “spike” protein that normally connects to a receptor on human cells to begin the process of cell infection. Many of the antibodies that neutralize SARS-CoV-2 appear to do so by blocking this virus-receptor connection.

“We were able to reveal unique structural features of these IGHV3-53-encoded antibodies–features that facilitate their high binding affinity and their specificity for the SARS-CoV-2 receptor binding site,” says co-first author Meng Yuan, PhD, a postdoctoral research associate in the Wilson lab.

The detailed atomic-scale structural data should be of interest to vaccine designers and drug developers. Moreover, the researchers say, the identification of IGHV3-53-encoded antibodies as key elements of the immune response to COVID-19 suggests that levels of these antibodies might be useful as an indirect marker of success in ongoing and future vaccine trials.

 

Contacts and sources:
Kelly Quigley

Scripps Research Institute

Publication:
“Structural basis of a shared antibody response to SARS-CoV-2″ was written by first authors Meng Yuan, Hejun Liu, and Nicholas Wu, all of the Wilson lab; and by Chang-Chun Lee, Xueyong Zhu, Fangzhu Zhao, Deli Huang, Wenli Yu, Yuanzi Hua, Henry Tien, Thomas Rogers, Dennis Burton, and Ian Wilson, all of Scripps Research; and Elise Landais, Devin Sok and Joseph Jardine of IAVI.

The research was supported by the National Institutes of Health (K99 AI139445, UM1 AI44462), the Bill and Melinda Gates Foundation (OPP1170236) and IAVI.

 



Source:


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com

Order by Phone at 888-809-8385 or online at https://www.herbanomic.com


Get our Free Ebook, "Suppressed Health Secrets"  with  Natural Cures THEY don't want you to know!

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Organic Hemp Extract (CBD) - Full Spectrum high CBD (3300mg) hemp extract eases stiff joints, relieves stress and more!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse
Loading...
Loading...

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Total 1 comment
  • Fake News = The False Prophet

    As you can see from the below brief intro to Scripps they form part of the Cesspit Medical mafia:

    The Scripps Research Translational Institute, formerly named Scripps Translational Science Institute (STSI), was founded in 2007 with one essential aim—to individualize healthcare by leveraging the remarkable progress being made in human genomics and combining it with the power of wireless digital technologies. By recognizing that every patient is unique, individualized healthcare tailors medical care to the patient, taking into account not only a person’s genes, but also their environment, behavior and lifestyle. Bringing together basic scientists and clinical investigators, the Translational Institute fosters highly collaborative multidisciplinary research with the greatest potential to transform the practice of healthcare and improve human health.

    A new study from the Scripps Research Translational Institute suggests that devices such as Fitbits may serve as valuable tools for population health, generating data that can alert health officials to emerging outbreaks in real time.

    Using de-identified data from Fitbit devices that were equipped with sleep- and heart rate-tracking capabilities, scientists were able to show that they could significantly improve predictions of influenza-like illness at the state level when compared with data from Centers for Disease Control and Prevention (CDC). The findings appear in The Lancet Digital Health.

    When the Scripps Research scientists added aggregated Fitbit variables, such as resting heart rate and sleep data, into a model that included CDC’s surveillance data

    The ability to predict what’s happening now and in the very near future is known as “nowcasting.” The term, once applied mainly to economics, is also used among epidemiologists who track the health of populations. Other health nowcasting methods, such as Google Flu Trends and Twitter, can be influenced by outside factors like media coverage. Wearable data, by contrast, has the benefit of being objective.

    “With access to 24/7 real-time data from these devices, I can envision a time when it may be possible to identify illness rates on a daily basis rather than weekly, providing even more timely surveillance,” Radin says. “This sensor-based tracking technique could even hold value on a more global level, in situations where disease surveillance sites and laboratories are not always available.”

    Other authors of the study, “Harnessing wearable device data to improve state-level real-time surveillance of influenza-like illness in the USA: a population-based study,” were Nathan Wineinger, Eric Topol and Steven Steinhubl of the Scripps Research Translational Institute.

    This research was supported by funding by the National Institutes of Health NCATS Clinical and Translational Science Awards (UL1TR002550). Fitbit did not have any role in study design, execution or funding.

    Networks

    Researchers at the Scripps Research Translational Institute work closely with local, national and international partners to further our aim of individualizing healthcare. We are a member of a number of research consortia that include leading academic institutions and commercial entities.

    NVIDIA
    Scripps Research Translational Institute and NVIDIA are collaborating to develop deep learning tools and methods to process and analyze genomic and digital medical sensor data.

    The partnership seeks to accelerate the application of artificial intelligence (AI) for disease prevention, health promotion and the streamlining of biomedical research efforts. Scripps and NVIDIA will focus on advancing the use of deep learning, a subset of AI that is poised to play a key role in improving clinical outcomes and reducing healthcare costs.

    While the use of computer-aided diagnostics is not new in medicine, the use of AI systems is currently largely limited to diagnoses from medical imaging. Preliminary studies, however, suggest that deep learning techniques could also be applied to big data of whole genomic sequences and continuous physiologic sensors, with potential to prevent illness. In deep learning, machine learning happens in layers, forming neural networks with each layer adding to the knowledge of the previous layers.

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.